moxifloxacin has been researched along with isoniazid in 159 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (isoniazid) | Trials (isoniazid) | Recent Studies (post-2010) (isoniazid) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 21,815 | 960 | 4,493 |
| Protein | Taxonomy | moxifloxacin (IC50) | isoniazid (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 4.85 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 8.29 | |
| Putative FAD-containing monooxygenase MymA | Mycobacterium tuberculosis H37Rv | 4.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (17.61) | 29.6817 |
| 2010's | 101 (63.52) | 24.3611 |
| 2020's | 30 (18.87) | 2.80 |
| Authors | Studies |
|---|---|
| Andries, K; Chauffour, A; Ibrahim, M; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Bitting, C; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Woolhiser, L | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Franzblau, SG; Kozikowski, AP; Lilienkampf, A; Pieroni, M; Wan, B; Wang, Y | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chibale, K; Franzblau, SG; Guantai, EM; Gut, J; Hans, RH; Lategan, C; Rosenthal, PJ; Smith, PJ; Wan, B | 1 |
| Angulo-Barturen, I; Beltrán, M; Cáceres, N; Cardona, PJ; García, JI; García-Bustos, JF; Rullas, J | 1 |
| Bishai, WR; Grosset, JH; Nuermberger, EL; Zhang, T | 1 |
| Ackerman, M; Cynamon, MH; Pucci, MJ; Shoen, CM; Thanassi, JA | 1 |
| Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ | 1 |
| Charnock, C; Franzblau, S; Gundersen, LL; Khoje, AD; Kulendrn, A; Wan, B | 1 |
| Chibale, K; Franzblau, SG; Gut, J; Hans, RH; Rosenthal, PJ; van Helden, PD; Wan, B; Wiid, IJ | 1 |
| Balzarini, J; Chibale, K; Franzblau, S; Singh, K; Wan, B | 1 |
| Aguinaldo, MA; Chen, X; Cordell, GA; Decker, M; Franzblau, SG; Galvez, EV; Heilmann, J; Macabeo, AP; Vidar, WS; Wan, B | 1 |
| Franzblau, SG; Garcia, GA; Gill, SK; Jin, Y; Kirchhoff, PD; Showalter, HD; Wan, B | 1 |
| Chen, L; Franzblau, SG; Liu, X; Lu, X; Wan, B; You, Q; Zhou, C | 1 |
| Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N | 1 |
| Cierpicki, T; Franzblau, SG; Garcia, GA; Gill, SK; Kirchhoff, PD; Peng, KW; Showalter, HD; Turbiak, AJ; Wan, B; Xu, H; Zhang, N | 1 |
| Dulla, B; Franzblau, SG; Iqbal, J; Kapavarapu, R; Pal, M; Reiser, O; Wan, B | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Barry, CE; Dartois, V | 1 |
| Ambady, A; Bandodkar, B; Bhat, J; Davies, G; Hameed, S; Hegde, N; Holdgate, G; Kumar, A; Madhavapeddi, P; McMiken, H; Murugan, K; Naik, M; Nandishaiah, R; Panda, M; Read, JA; Sambandamurthy, VK; Shinde, V; Shirude, PS; Venkatraman, J | 1 |
| Achar, V; Arora, U; Awasthy, D; Bharath, S; Bheemarao, U; Chinnapattu, M; Coulson, M; de Sousa, SM; Ganguly, S; Gaonkar, S; Ghosh, A; Hameed P, S; Hoffner, S; Humnabadkar, V; Kaur, P; Kumar K N, M; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Menasinakai, S; Mukherjee, K; Nandishaiah, R; Narayan, C; Panduga, V; Patil, V; Puttur, J; Raichurkar, A; Ramya, VK; Reddy, J; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Sharma, U; Shinde, V; Solapure, S; Waterson, D; Werngren, J | 1 |
| Achar, V; Ambady, A; Awasthy, D; Bathula, C; Binda, C; Chatterji, M; Chiarelli, LR; Dhar, N; Dinesh, N; Ghorpade, SR; Gorai, G; Guptha, S; Hegde, N; Hosagrahara, V; Humnabadkar, V; Iyer, PS; Jatheendranath, S; Jena, LK; Kaur, P; Kavanagh, S; Koushik, K; Madhavapeddi, P; Mahadevaswamy, J; Manjrekar, P; Manjunatha, MR; McKinney, JD; McLaughlin, B; Naik, M; Narayan, A; Narayan, C; Narayanan, S; Neres, J; Panda, M; Panduga, V; Pasca, MR; Prabhakar, K; Ramachandran, V; Ravishankar, S; Reddy, J; Riccardi, G; Rudrapatna, S; Sambandamurthy, VK; Saralaya, R; Shanbhag, G; Shandil, R; Sharma, S; Signorino-Gelo, F; Tantry, SJ; Tommasi, R; Whiteaker, J | 1 |
| Ambady, A; Butler, S; Chatterji, M; Cooper, CB; Humnabadkar, V; Iyer, PS; Jena, LK; Manjunatha, MR; McLaughlin, RE; Mdluli, K; Nanduri, R; Narayanan, S; Panda, M; Panduga, V; Prabhakar, KR; Ravishankar, S; Reddy, J; Sadler, C; Sambandamurthy, VK; Saralaya, R; Shandil, RK; Sharma, S; Shirude, PS; Srivastava, A; Suresh, RS; Whiteaker, J | 1 |
| Cho, S; Franzblau, SG; Markley, LD; Miller, MJ; Moraski, GC; Oliver, AG | 1 |
| Achar, V; Ambady, A; Awasthy, D; Bandodkar, B; Bellale, E; Chatterji, M; Guptha, S; Kaur, P; McLaughlin, R; Morayya, S; Naik, M; Narayan, A; Panda, M; Raichurkar, A; Ramachandran, V; Ravishankar, S; Sharma, S; V B, V; Vachaspati, P; Whiteaker, J | 1 |
| Hameed P, S; Kaur, P; Madhavapeddi, P; Menasinakai, S; Nandishaiah, R; Panduga, V; Raichurkar, A; Reddy, J; Sambandamurthy, VK; Sharma, S; Sriram, D | 1 |
| Babu, KS; Jeankumar, VU; Reddy, KI; Renuka, J; Shravan, M; Sridevi, JP; Srihari, K; Sriram, D; Yogeeswari, P | 1 |
| Guo, H; Huang, J; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, J; Wang, M | 1 |
| Balakrishnan, G; Bhat, J; Chatterji, M; Dinesh, N; Ghorpade, S; Gorai, G; Guptha, S; Humnabadkar, V; Iyer, PS; Jena, LK; Kaur, P; Khadtare, P; Naik, M; Nandishaiah, R; Narayan, A; Naviri, LK; Panda, M; Ramachandran, V; Sharma, S | 1 |
| Devi, PB; Samala, G; Saxena, S; Sridevi, JP; Sriram, D; Yogeeswari, P | 1 |
| Kulkarni, P; Medapi, B; Medishetti, R; Renuka, J; Saxena, S; Sridevi, JP; Sriram, D; Yogeeswari, P | 1 |
| Chinnapattu, M; Hameed P, S; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Nandishaiah, R; Patil, V; Puttur, J; Raichurkar, A; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Shinde, V; Solapure, S; Sriram, D | 1 |
| Medapi, B; Renuka, J; Sridevi, JP; Sriram, D; Suryadevara, P; Yogeeswari, P | 1 |
| Huang, J; Li, L; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, C; Wang, M; Zhang, R | 1 |
| Kulkarni, P; Meda, N; Medapi, B; Sriram, D; Yogeeswari, P | 1 |
| Devi, PB; Meda, N; Samala, G; Saxena, S; Sriram, D; Yogeeswari, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Feng, L; Huang, J; Li, X; Liu, M; Lu, Y; Wang, B; Wang, M; Wu, Z; Yang, Y; Zhang, J | 1 |
| Bobesh, KA; Gunda, S; Jeankumar, VU; Reshma, RS; Saxena, S; Sriram, D; Yogeeswari, P | 1 |
| Brindha Devi, P; Gunda, S; Samala, G; Saxena, S; Sriram, D; Yogeeswari, P | 1 |
| Abbadi, BL; Back, DF; Basso, LA; Campos, MM; Giacobbo, BC; Grams, ES; Machado, P; Pissinate, K; Rodrigues-Junior, V; Santos, DS; Sperotto, N; Subtil, FT; Trindade, RV; Villela, AD | 1 |
| Bobesh, KA; Jeankumar, VU; Kapoor, N; Kolattukudy, PE; Reshma, RS; Saxena, S; Sriram, D; Vachaspathy, AR | 1 |
| Bosquesi, PL; Chegaev, K; Cho, SH; Chorilli, M; da Silva, PB; de Carvalho, LPS; de Souza Costa, CA; de Souza, PC; Dos Santos Fernandes, GF; Dos Santos, JL; Franzblau, SG; Fruttero, R; Guglielmo, S; Hunt, DM; Lazzarato, L; Man Chin, C; Marino, LB; Moreno-Viguri, E; Paucar, R; Pavan, FR; Pérez-Silanes, S; Ribeiro, CM; Santivañez-Veliz, M; Silva, CSP; Solcia, MC; Wang, Y | 1 |
| Malapati, P; Meda, N; Nallangi, R; Reshma Srilakshmi, R; Siva Krishna, V; Sriram, D | 1 |
| Bonnet, M; Cooper, CB; Denny, WA; Franzblau, SG; Lee, HH; Thompson, AM; Wan, B; Wong, GS | 1 |
| Krishna, VS; Malapati, P; Nallangi, R; Srilakshmi, RR; Sriram, D | 1 |
| Alfonso, S; Ballell, L; Barros Aguirre, D; Bates, RH; Biava, M; Cocozza, M; Consalvi, S; De Logu, A; Fernandez-Menendez, R; Poce, G; Venditti, G; Vistoli, G | 1 |
| Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ | 1 |
| Franzblau, SG; Hu, X; Liu, Z; Lu, X; Wan, B; Wang, R; You, Q; Zhang, T | 1 |
| Charrier, C; Cooper, IR; Kerr, WJ; Lindsay, DM; Maclean, J; McGarry, DH; Moyo, E; Pichowicz, M; Ratcliffe, AJ; Salisbury, AM; Savage, VJ; Smith, A; Stokes, NR; Walker, R; Warrilow, CE | 1 |
| Eswaran, S; Narayanan, S; Shivarudraiah, P; Shruthi, TG; Subramanian, S | 1 |
| Bai, L; Deng, JL; Gao, F; Lv, ZS; Wang, Y; Xu, Z; Zhang, F; Zhao, SJ | 1 |
| da Silva Emery, F; de Melo, SMG; Fumagalli, F; Pavan, FR; Ribeiro, CM; Solcia, MC | 1 |
| Bishai, WR; Duan, G; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Xiao, S; Yang, F; Yu, LF; Zhang, W | 1 |
| Chen, L; Chen, Z; Fan, Y; Gao, F; Lu, G; Ma, L | 1 |
| Caljon, G; Cappoen, D; Claes, P; Cools, F; Cos, P; De Kimpe, N; de Macedo, MB; Delputte, P; Holvoet, F; Maes, L; Mangelinckx, S; Matheeussen, A; Meiresonne, T; Neyrolles, O; Piller, T; Semina, E; Torfs, E; Van Calster, K | 1 |
| Alfonso, S; Ballell, L; Barros Aguirre, D; Bates, RH; Biava, M; Consalvi, S; De Logu, A; Desideri, N; Fernandez-Menendez, R; Gardner, M; Ioerger, TR; Poce, G; Rubin, EJ; Rullas, J; Venditti, G | 1 |
| Bangalore, PK; Bollikanda, RK; Choudante, PC; Kantevari, S; Misra, S; Sridhar, B; Sriram, D; Vagolu, SK; Veeragoni, DK | 1 |
| Krishna, VS; Sirim, MM; Sriram, D; Unsal Tan, O | 1 |
| George, SE; Guddat, LW; Krishna, VS; Nallangi, R; Rekha, EM; Sai Prasad, DV; Sriram, D; Zheng, S | 1 |
| Begum, N; Bhakta, S; Castagnolo, D; Gupta, A; Kyriazi, M; Manetti, F; McHugh, TD; Pavan, FR; Ribeiro, CM; Scalacci, N; Semenya, D; Senderowitz, H; Touitou, M; Zrebna, K | 1 |
| Cappoen, D; Cos, P; De Ruysscher, D; Lenders, SMG; Pang, L; Rozenski, J; Strelkov, SV; Van Aerschot, A; Weeks, SD | 1 |
| Bano, G; Castagnolo, D; Chibale, K; Gianibbi, B; Manetti, F; Pavan, FR; Pisano, L; Ribeiro, CM; Semenya, D; Singh, V; Toscani, A; Touitou, M | 1 |
| Castagnolo, D; Dos Santos Fernandes, GF; Gianibbi, B; Manetti, F; Masci, D; Pavan, FR; Ribeiro, CM; Semenya, D; Touitou, M | 1 |
| Chen, S; Ding, CZ; Franzblau, SG; Guo, F; Huang, Z; Li, L; Li, Y; Luo, W; Shen, L; Tang, D; Wang, B; Xu, D; Yang, M; Zhu, Y | 1 |
| Bin, W; Chen, S; Ding, CZ; Franzblau, SG; Hu, Y; Huang, Z; Jiang, N; Luo, W; Shen, L; Tao, X; Wei, X; Wei, Y; Xu, D; Yang, M; Zhu, Y | 1 |
| Cheon, SH; Dietze, R; Ellner, JJ; Hise, AG; Landen, K; Palaci, M; Phillips, M; Ribeiro, FC; Song, HY; Vinhas, S; Wallis, RS | 1 |
| Bentoucha, A; Grosset, J; Ji, B; Lounis, N; O'Brien, RJ; Roscigno, G; Truffot-Pernot, C; Vernon, A | 1 |
| Alvirez-Freites, EJ; Carter, JL; Cynamon, MH | 1 |
| Bellanova, S; Bracciale, P; Legari, G; Manisco, V; Quitadamo, M; Valerio, G | 1 |
| Bongard, E; Gillespie, SH; Gosling, RD; Kanduma, EG; Morris, RW; Nyindo, M; Sam, NE; Uiso, LO | 1 |
| Au-Yeang, C; Chan, CY; Cheng, AF; Leung, CC; Yew, WW | 1 |
| De Roux, A; Lode, H; Mauch, H; Neumann, KH; Pletz, MW; Roth, A | 1 |
| Gillespie, S; Gosling, R | 1 |
| Cokolova, GB; Elistratova, NA; Lazareva, IaV; Mozhokina, GN; Perel'man, MI; Strekchev, AIu | 1 |
| Gillespie, SH; Gosling, RD; Kanduma, EG; McHugh, TD; Sam, NE; Uiso, L | 1 |
| Ader, F; Bernard, L; Carlier, R; Perronne, C; Salomon, J; Toubiana, J | 1 |
| Drobniewski, FA; Krüüner, A; Yates, MD | 1 |
| Bishai, WR; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, K | 1 |
| Chau, CH; Wong, HY; Yew, WW | 1 |
| Kubendiran, G; Mitchison, DA; Paramasivan, CN; Sulochana, S | 1 |
| Aarnoutse, RE; Alisjahbana, B; Burger, DM; Nijland, HM; Ruslami, R; Suroto, AJ; van Crevel, R | 1 |
| Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M | 1 |
| Allen, J; Coleman, DJ; Davies, GR; Fourie, B; Kanyok, T; Levin, J; Lienhardt, C; Mitchison, DA; Mthiyane, T; Reddy, C; Rustomjee, R; Sirgel, FA; Sturm, AW | 1 |
| Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M | 1 |
| Bishai, WR; Cezar, MC; Chaisson, RE; Chaudhary, MA; Conde, MB; De Souza, GR; Efron, A; Graça, NP; Kritski, AL; Loredo, C; Ram, M | 1 |
| Bernardo, J; Bozeman, L; Chaisson, RE; Choudhri, S; Dorman, SE; Goldberg, S; Grosset, JH; Guy, E; Guyadeen, P; Heilig, CM; Johnson, JL; Leus, MC; Maltas, G; Menzies, D; Muzanye, G; Nuermberger, EL; Padayatchi, N; Vernon, A; Villarino, M | 1 |
| Kubendiren, G; Mitchison, DA; Paramasivan, CN; Sulochana, S; Venkatesan, P | 1 |
| Mohapatra, PR | 1 |
| Gumbo, T | 1 |
| Oliver, GF; Wong, KK | 1 |
| Cole, ST; Dhar, N; Ha, YH; Hartkoorn, RC; Sala, C; Schneider, P; Zhang, M | 1 |
| DeGroote, MA; Gilliland, JC; Kendall, LV; Lenaerts, AJ; Magden, ER; Weiner, CM | 1 |
| Achawal, S; Anderson, G; Lee, WY; Ling, M; Thaker, HK | 1 |
| Cremades, R; Galiana, A; García-Pachón, E; López, P; Rodríguez, JC; Royo, G; Ruiz-García, M | 1 |
| Colucci, G; Silzle, T; Solenthaler, M | 1 |
| Barry, CE; Dartois, V; Goh, A; Kern, S; Kjellsson, MC; Low, KM; Pillai, G; Via, LE; Weiner, D | 1 |
| Braissant, O; Daniels, AU; Howell, M; Wirz, D | 1 |
| Hamilton, CD; Holland, DP; Sanders, GD; Stout, JE | 1 |
| Aarnoutse, RE; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; Kremer, K; ten Kate, MT; van Soolingen, D; Verbrugh, HA | 1 |
| Fu, L; Jin, H; Li, P; Lu, Y; Mdluli, K; Upton, AM; Wang, B; Xu, J; Zhao, W; Zheng, M; Zhu, H | 1 |
| Cole, ST; Hartkoorn, RC; Lechartier, B | 1 |
| Geetharani, A; Hemanth Kumar, AK; Nandhakumar, B; Nandini, R; Ramachandran, G; Srinivasan, R; Sugirda, P; Tharani, CB | 1 |
| Alcántara, F; Atwood, SS; Becerra, MC; Bonilla, CA; Mitnick, CD; Seung, KJ | 1 |
| Alland, D; Armakovitch, S; Armstrong, DT; Barry, CE; Chien, G; Cho, SN; Dorman, SE; Ellner, JJ; Joloba, ML; Lee, J; Mboowa, G; Mumbowa, F; Nakayita, G; Namaganda, C; Park, JA; Ssengooba, W; Via, LE; Yu, Y | 1 |
| Blyth, CC; Colby, S; Fagan, JM; Francis, JR; Waring, J | 1 |
| Elkington, PT; Friedland, JS; Gardiner, H; Kubler, A; Prasad, R; Singh, A; Singh, S; Singh, UK | 1 |
| Adrián Cataldi, A; Di Giulio, ÁB; Imperiale, BR; Morcillo, NS | 1 |
| Crook, AM; Gillespie, SH; McHugh, TD; Mendel, CM; Meredith, SK; Murray, SR; Nunn, AJ; Pappas, F; Phillips, PP | 1 |
| Chiang, CY; Madan, J; Meredith, SK; Nunn, AJ; Phillips, PP; Rusen, ID; Squire, SB; Torrea, G; Van Deun, A | 1 |
| de Droogh, E; Groenen, G; Mathys, V; Soetaert, K; van de Vyvere, M | 1 |
| Bateson, AL; Butcher, PD; Charalambous, S; Churchyard, GJ; Clouting, HE; Coleman, D; Geldenhuys, H; Harrison, TS; Hatherill, M; Jindani, A; Magweta, L; McHugh, TD; McIlleron, HM; Mitchison, DA; Mungofa, S; Nunn, AJ; Nyirenda, S; Phillips, PP; Shah, NA; Shepherd, J; van Dijk, JH; Zizhou, S; Zvada, SP | 1 |
| Adelakun, A; Bhatnagar, V; Chen, Q; Emadi, A; Farshidpour, M; Holtzman, N; Kendall, T; Stevenson, B | 1 |
| Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F | 1 |
| Boutou, A; Chatzika, K; Kioumis, I; Kontou, P; Manika, K; Papaioannou, M; Zarogoulidis, K | 1 |
| Huh, HJ; Jeon, K; Jeong, BH; Koh, WJ; Lee, H; Lee, NY; Park, HY | 1 |
| Hussain, T; Moin, A; Nagshubha, B; Raizaday, A | 1 |
| Armstrong, DT; Barnes, GL; Cavalcante, SC; Chaisson, RE; Cohn, S; Conde, MB; Dalcolmo, M; Dooley, KE; Dorman, SE; Duarte, RS; Durovni, B; Efron, A; Loredo, C; Marzinke, MA; Mello, FC; Moulton, LH; Rolla, V; Savic, RM | 1 |
| Lu, JM; Sha, W; Xiao, HP; Yang, H; Zhang, LL; Zhang, Q | 1 |
| Darley, DR; Glanville, AR; Goeman, EE; Jensen, TO; Marriott, DJ; Shaw, K | 1 |
| Blackmore, T; McNaughton, A; McNaughton, H | 1 |
| Centis, R; D'Ambrosio, L; Fuentes, Z; Migliori, GB; Sotgiu, G; Tiberi, S; Zumla, A | 1 |
| Kreiswirth, BN; Kurepina, N; Meinke, PT; Olsen, DB; Singh, SB; Xu, L; Young, K | 1 |
| Aarnoutse, R; Boeree, MJ; Charalambous, S; Churchyard, G; Colbers, A; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; Heinrich, N; Henne, S; Hoelscher, M; Hunt, RD; Kibiki, GS; Manyama, C; Mekota, A; Minja, LT; Mpagama, SG; Mtafya, B; Narunsky, K; Ntinginya, NE; Phillips, PPJ; Rehal, S; Reither, K; Sanne, I; Semvua, HH; van Balen, GP; Venter, A; Wallis, RS | 1 |
| Mendel, C; Murray, S; Spigelman, M | 1 |
| Babrak, L; Bermudez, LE; Burrows, G; Chinison, JJJ; Danelishvili, L; Hu, J; Morgun, A; Shulzhenko, N | 1 |
| Campanerut-Sá, PAZ; Cardoso, RF; Ghiraldi-Lopes, LD; Meneguello, JE; Pavan, FR; Scodro, RBL; Siqueira, VLD; Svidzinski, TIE; Teixeira, JJV | 1 |
| Clifton, DA; Crook, DW; Iqbal, Z; Niehaus, KE; Peto, TEA; Smith, EG; Walker, AS; Walker, TM; Wilson, DJ; Yang, Y; Zhu, T | 1 |
| Caminero Luna, JA; Cerezo Lajas, A; de Miguel Díez, J; Rodríguez Guzmán, MDC | 1 |
| Carrera-Pineda, R; Garcia-Luna, RC; Soto-Cabrera, E; Villamil-Osorio, LV | 1 |
| Coates, AR; Davies, GR; Gillespie, SH; Hu, Y; Liu, Y; Pertinez, H | 1 |
| Amukoye, EI; Crook, AM; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; McHugh, TD; Mendel, CM; Meredith, SK; Murphy, ME; Murthy, SE; Nunn, AJ; Phillips, PPJ; Singh, KP; Spigelman, M; Tweed, CD; Wills, GH | 1 |
| Cao, P; Doan, TN; Emeto, TI; McBryde, ES; McCaw, JM | 1 |
| Chigutsa, E; Deshpande, D; Gumbo, T; Magombedze, G; McIlleron, H; Pasipanodya, JG; Srivastava, S; Visser, ME | 1 |
| Berney, M; Hasenoehrl, EJ; Jin, XEF; Kalia, NP; Lee, BS; Pethe, K | 1 |
| Ajitkumar, P; Nair, RR; Paul, A; Pradhan, A; Sebastian, J; Swaminath, S | 1 |
| Alameer, R; Almaghrabi, RS; Almohaizeie, A; Alrajhi, AA; Alshehri, N; Nizami, I; Omrani, AS | 1 |
| Ahmad, N; Atif, M; Ghafoor, A; Iqbal, Q; Khan, S; Latif, A; Saleem, F; Wahid, A | 1 |
| Bishai, W; Dawson, R; De Jager, V; Diacon, A; Donahue, K; Fletcher, CV; Hafner, R; Hogg, E; Miyahara, S; Sun, X; Swindells, S; Urbanowski, M | 1 |
| Chen, W; Cheng, NC; Fang, G; Hu, CM; Huang, LL; Xie, WP | 1 |
| Allen, L; Carr, W; Goswami, N; Kurbatova, E; Starks, A; Winston, C | 1 |
| Guo, Y; Liu, H; Sha, W; Shen, H; Shen, X; Tan, G; Wu, X; Wu, Z; Yang, J; Yu, F | 1 |
| Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD | 1 |
| Guo, Y; Huang, C; Sha, W; Tan, G; Wu, X; Yang, J; Yu, F | 1 |
| Arodola-Oladoyinbo, O; Chirehwa, M; Denti, P; Gengiah, TN; Kawuma, AN; Naidoo, A; Naidoo, K; Padayatchi, N; Perumal, R | 1 |
| Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z | 1 |
| Al-Zubaidi, A; Cheung, CY; Cook, GM; Dawes, SS; Lott, JS; Mizrahi, V; Taiaroa, G | 1 |
| Brankin, A; Colman, RE; Georghiou, SB; Seifert, M; Suresh, A; Uplekar, S; Walker, TM | 1 |
| Du, Y; Huang, H; Huang, J; Jia, J; Nong, Y; Song, W; Tan, Q; Xiao, X; Xu, J; Zhong, R; Zhu, R | 1 |
| Dartois, V; Mittereder, LR; Namasivayam, S; Oland, S; Sher, A; Wang, H; Zimmerman, M | 1 |
| Chen, X; Feng, Z; Ge, S; Li, R; Li, Y; Miao, Y; Peng, Y; Song, L; Sun, F; Wang, X; Zhang, W; Zhang, Y | 1 |
| Brehm, TT; Friesen, I; Heyckendorf, J; Kalsdorf, B; Kandulla, J; Köhler, N; Kuhns, M; Lange, C; Martensen, J; Schmiedel, S; Terhalle, E | 1 |
| Alffenaar, JW; Aryal, S; Boorgula, GD; Dheda, K; Gumbo, T; Malinga, L; Raj, P; Shankar, P; Singh, S; Srivastava, S; Thomas, TA | 1 |
| Berge, I; Bogdanova, I; Freimane, L; Norvaiša, I; Ozere, I; Ranka, R; Sadovska, D; Vaivode, A; Vīksna, A | 1 |
| Aalhoul, F; Cotton, F; Fage, D | 1 |
| Adeel, A; Ahmad, A; Ahmad, I; Aslam, H; Mushtaq, F; Raza, SM; Saleem, S | 1 |
8 review(s) available for moxifloxacin and isoniazid
| Article | Year |
|---|---|
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Lung; Mycobacterium tuberculosis; Tuberculosis | 2013 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis | 2018 |
Fluoroquinolone-isatin hybrids and their biological activities.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Fluoroquinolones; Humans; Isatin; Structure-Activity Relationship | 2019 |
Systematic review on the proteomic profile of Mycobacterium tuberculosis exposed to drugs.
Topics: Anti-Bacterial Agents; Electrophoresis, Gel, Two-Dimensional; Fluoroquinolones; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Proteome; Proteomics; Streptomycin | 2017 |
The first report of co-existence of pulmonary tuberculosis and lung malignancy in a kidney transplant recipient: a case report and literature review.
Topics: Adenocarcinoma; China; Ethambutol; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Isoniazid; Kidney Transplantation; Lung; Lung Neoplasms; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Positron Emission Tomography Computed Tomography; Thoracic Surgery, Video-Assisted; Treatment Outcome; Tuberculosis, Pulmonary | 2021 |
[Treatment of tuberculosis: what is new?]
Topics: Antitubercular Agents; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |
16 trial(s) available for moxifloxacin and isoniazid
| Article | Year |
|---|---|
The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Aza Compounds; Female; Fluoroquinolones; Humans; Inhibitory Concentration 50; Isoniazid; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Sputum; Tuberculosis, Pulmonary | 2003 |
Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Female; Fluoroquinolones; Humans; Isoniazid; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Prospective Studies; Quinolines; Sputum; Tuberculosis, Pulmonary | 2004 |
[Optimization of tuberculosis complex chemotherapy with the use of moxifloxacin].
Topics: Adolescent; Adult; Animals; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Mice; Middle Aged; Moxifloxacin; Pyrazinamide; Quinolines; Tuberculosis, Pulmonary | 2004 |
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Aza Compounds; Drug Interactions; Female; Fluoroquinolones; Humans; Indonesia; Isoniazid; Male; Middle Aged; Moxifloxacin; Plasma; Quinolines; Rifampin; Tuberculosis, Pulmonary | 2007 |
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Nonlinear Dynamics; Ofloxacin; Pyrazinamide; Quinolines; Rifampin; Sputum | 2008 |
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Kaplan-Meier Estimate; Logistic Models; Male; Moxifloxacin; Multivariate Analysis; Pyrazinamide; Quinolines; Rifampin; Sputum; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2009 |
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Follow-Up Studies; Humans; Isoniazid; Male; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Retrospective Studies; Sputum; Treatment Outcome; Tuberculosis, Pulmonary | 2009 |
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult | 2014 |
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.
Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Moxifloxacin; Prothionamide; Pyrazinamide; Research Design; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult | 2014 |
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul
Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2015 |
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 2016 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Ethylenediamines; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Rifampin; South Africa; Tanzania; Tuberculosis, Pulmonary | 2017 |
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis | 2020 |
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary | 2023 |
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
Topics: Clinical Trials, Phase II as Topic; Humans; Isoniazid; Moxifloxacin; Multicenter Studies as Topic; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis | 2023 |
135 other study(ies) available for moxifloxacin and isoniazid
| Article | Year |
|---|---|
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Drug Synergism; Female; Lung; Mice; Organ Size; Pyrazinamide; Quinolines; Spleen; Survival Analysis; Tuberculosis, Pulmonary | 2007 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
Topics: Animals; Antitubercular Agents; Biological Availability; Interferon-gamma; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridones; Quinolones; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.
Topics: Antitubercular Agents; Carboxylic Acids; Esters; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Synthesis, antimalarial and antitubercular activity of acetylenic chalcones.
Topics: Alkynes; Antimalarials; Antitubercular Agents; Chalcones; Mycobacterium tuberculosis; Plasmodium falciparum | 2010 |
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; Ethambutol; Fluoroquinolones; Immunocompetence; Inhalation Exposure; Isoniazid; Linezolid; Mice; Mice, Inbred C57BL; Moxifloxacin; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Rifampin; Tuberculosis, Pulmonary | 2010 |
Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.
Topics: Anti-Bacterial Agents; Erythromycin; Luminescent Proteins; Microbial Sensitivity Tests; Models, Genetic; Mycobacterium ulcerans; Reserpine; Tetracycline | 2010 |
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolones; Thiazoles; Topoisomerase II Inhibitors; Tuberculosis | 2010 |
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin | 2010 |
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Drug Resistance, Bacterial; Imidazoles; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Purines; Vero Cells | 2010 |
Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.
Topics: Animals; Antimalarials; Antitubercular Agents; Isatin; Lactones; Mycobacterium tuberculosis; Plasmodium falciparum; Structure-Activity Relationship | 2011 |
Facile transformation of Biginelli pyrimidin-2(1H)-ones to pyrimidines. In vitro evaluation as inhibitors of Mycobacterium tuberculosis and modulators of cytostatic activity.
Topics: Animals; Antitubercular Agents; Cell Proliferation; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Mice; Molecular Structure; Mycobacterium tuberculosis; Pyrimidines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.
Topics: Acetylcholinesterase; Alkaloids; Animals; Antitubercular Agents; Butyrylcholinesterase; Cholinesterase Inhibitors; Electrophorus; Horses; Indole Alkaloids; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazines; Pentacyclic Triterpenes; Plant Extracts; Plant Leaves; Spiro Compounds; Structure-Activity Relationship; Voacanga; Xanthenes | 2011 |
Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin.
Topics: Antitubercular Agents; Escherichia coli; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazoles; Rifampin; Rifamycins; Tuberculosis | 2011 |
Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Humans; Imidazoles; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazoles; Thiazoles; Tuberculosis | 2012 |
Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases.
Topics: Animals; Antibiotics, Antitubercular; Benzoxazines; DNA-Directed RNA Polymerases; Drug Design; Drug Resistance, Bacterial; Mice; Mycobacterium tuberculosis; Rifampin; Rifamycins | 2012 |
Construction and functionalization of fused pyridine ring leading to novel compounds as potential antitubercular agents.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Ligands; Models, Molecular; Molecular Structure; Pyridines; Structure-Activity Relationship; Vero Cells | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
Topics: Bacterial Proteins; Crystallography, X-Ray; Dose-Response Relationship, Drug; Enzyme Inhibitors; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Oxidoreductases; Structure-Activity Relationship; Thiazoles | 2013 |
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Topics: Acute Disease; Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Biological Availability; Chronic Disease; DNA Gyrase; Drug Resistance, Bacterial; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Macrophages; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Mutation; Mycobacterium tuberculosis; Piperidines; Protein Subunits; Rats; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tuberculosis, Pulmonary | 2014 |
4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
Topics: Alcohol Oxidoreductases; Amides; Animals; Antitubercular Agents; Bacterial Proteins; Catalytic Domain; Cell Line, Tumor; Drug Resistance, Bacterial; Genome, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Molecular Docking Simulation; Mutation; Mycobacterium tuberculosis; Oxidoreductases; Piperidines; Protein Binding; Quinolones; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship | 2014 |
Lead optimization of 1,4-azaindoles as antimycobacterial agents.
Topics: Alcohol Oxidoreductases; Animals; Antitubercular Agents; Bacterial Proteins; Cyclic Nucleotide Phosphodiesterases, Type 6; Disease Models, Animal; Humans; Indoles; Mice; Mycobacterium tuberculosis; Oxidoreductases; Rats; Structure-Activity Relationship | 2014 |
Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.
Topics: Antitubercular Agents; Bridged Bicyclo Compounds; Dose-Response Relationship, Drug; Heterocyclic Compounds; Hydrocarbons, Aromatic; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyridines; Pyrimidines; Structure-Activity Relationship | 2014 |
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; High-Throughput Screening Assays; Humans; Mice; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Polymorphism, Single Nucleotide; Protein Kinases; Small Molecule Libraries; Structure-Activity Relationship; Thiazoles | 2014 |
Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.
Topics: | 2014 |
Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Benzofurans; Cell Line; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Fluoroquinolones; Microbial Sensitivity Tests; Molecular Structure; Oximes; Structure-Activity Relationship | 2014 |
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis.
Topics: | 2014 |
Design and development of novel Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors.
Topics: Alanine Dehydrogenase; Animals; Cell Line; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Macrophages; Mice; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2015 |
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.
Topics: Animals; Anti-Bacterial Agents; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium smegmatis; Mycobacterium tuberculosis; Piperidines; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Zebrafish | 2015 |
Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.
Topics: | 2015 |
4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
Topics: Aminoquinolines; Antitubercular Agents; DNA Gyrase; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2015 |
Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Levofloxacin; Moxifloxacin; Naphthyridines; Oximes; Pyrrolidines; Stereoisomerism | 2015 |
Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.
Topics: Acridines; Animals; Antitubercular Agents; Bacterial Proteins; Cell Line; Cell Survival; Chlorobenzoates; DNA Gyrase; Dose-Response Relationship, Drug; Embryo, Nonmammalian; Ether-A-Go-Go Potassium Channels; Gene Expression; Heart Rate; Macrophages; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Piperidines; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Zebrafish; Zebrafish Proteins | 2016 |
Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.
Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Peptide Synthases; Structure-Activity Relationship; Thiazoles; Zebrafish | 2016 |
Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Fluoroquinolones; Oximes | 2016 |
Design and development of new class of Mycobacterium tuberculosisl-alanine dehydrogenase inhibitors.
Topics: Alanine Dehydrogenase; Antitubercular Agents; Carbon-13 Magnetic Resonance Spectroscopy; Crystallography, X-Ray; Drug Design; Molecular Structure; Mycobacterium tuberculosis; Proton Magnetic Resonance Spectroscopy; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship | 2016 |
Anti-tubercular activities of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine analogues endowed with high activity toward non-replicative Mycobacterium tuberculosis.
Topics: Alanine Dehydrogenase; Antitubercular Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrimidines; Structure-Activity Relationship; Thiophenes | 2016 |
New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.
Topics: Acetamides; Animals; Antitubercular Agents; Drug Resistance, Bacterial; Drug Synergism; Humans; Macrophages; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolines; RAW 264.7 Cells; Structure-Activity Relationship | 2017 |
Mycobacterium tuberculosis lysine-ɛ-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors.
Topics: Antitubercular Agents; Bacterial Proteins; Benzothiazoles; Binding Sites; Catalytic Domain; Drug Design; Enzyme Inhibitors; Molecular Docking Simulation; Mycobacterium tuberculosis; Structure-Activity Relationship; Transaminases | 2017 |
Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.
Topics: Animals; Antitubercular Agents; Biological Availability; Caco-2 Cells; Heterocyclic Compounds; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxides; Spectrum Analysis | 2017 |
Lead identification and optimization of bacterial glutamate racemase inhibitors.
Topics: Amino Acid Isomerases; Animals; Antitubercular Agents; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; RAW 264.7 Cells; Structure-Activity Relationship | 2018 |
Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid.
Topics: | 2017 |
Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.
Topics: Amino Acid Isomerases; Animals; Anti-Bacterial Agents; Benzoxazoles; Biofilms; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Kinetics; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mycobacterium; RAW 264.7 Cells; Structure-Activity Relationship; Zebrafish | 2018 |
In vivo potent BM635 analogue with improved drug-like properties.
Topics: Animals; Antitubercular Agents; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Hep G2 Cells; Humans; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Structure-Activity Relationship; Tuberculosis | 2018 |
Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant
Topics: | 2017 |
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase.
Topics: Anti-Bacterial Agents; Cell Survival; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Multiple, Bacterial; Gram-Positive Bacteria; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Mycobacterium tuberculosis; Oxadiazoles; Quinolines; Structure-Activity Relationship | 2019 |
Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis.
Topics: Amination; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Furans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridines; Structure-Activity Relationship | 2019 |
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Polyketide Synthases; Structure-Activity Relationship; Vero Cells | 2019 |
Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
Topics: Animals; Antitubercular Agents; Cell Survival; Chlorocebus aethiops; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Isatin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Structure-Activity Relationship; Triazoles; Vero Cells | 2019 |
The synthesis and in vitro biological evaluation of novel fluorinated tetrahydrobenzo[j]phenanthridine-7,12-diones against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Benzophenanthridines; Cell Line; Dose-Response Relationship, Drug; Humans; Hydrocarbons, Fluorinated; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2019 |
Novel Pyrazole-Containing Compounds Active against
Topics: | 2019 |
Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacillus subtilis; Benzofurans; Lichens; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Triazoles | 2020 |
Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity.
Topics: Acrylonitrile; Anti-Bacterial Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2020 |
Design and development of ((4-methoxyphenyl)carbamoyl) (5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide analogues as Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors.
Topics: Amides; Animals; Antitubercular Agents; Biofilms; Cell Line; Dose-Response Relationship, Drug; Drug Development; Enzyme Inhibitors; HEK293 Cells; Humans; Ketol-Acid Reductoisomerase; Macrophages; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2020 |
Improving the Potency of
Topics: | 2020 |
Synthesis and structure-activity studies of novel anhydrohexitol-based Leucyl-tRNA synthetase inhibitors.
Topics: Anti-Bacterial Agents; Antifungal Agents; Candida albicans; Crystallography, X-Ray; Dose-Response Relationship, Drug; Enzyme Inhibitors; Escherichia coli; Leucine-tRNA Ligase; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Neisseria gonorrhoeae; Staphylococcus aureus; Structure-Activity Relationship; Sugar Alcohols | 2021 |
Structural Rigidification of
Topics: | 2022 |
Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation.
Topics: Animals; Antitubercular Agents; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrroles; Structure-Activity Relationship | 2022 |
Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent.
Topics: Animals; Antitubercular Agents; Long QT Syndrome; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2022 |
A whole blood bactericidal assay for tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Blood; Blood Bactericidal Activity; Culture Media; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Quinolines; Rifampin | 2001 |
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Resistance, Microbial; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Organ Size; Quinolines; Rifampin; Spleen; Streptomycin; Survival Rate; Tuberculosis | 2001 |
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Combinations; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nasal Cavity; Quinolines; Tuberculosis | 2002 |
Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results.
Topics: Aged; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Quinolines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2003 |
In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Drug Combinations; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin | 2004 |
Moxifloxacin treatment of tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Quinolines; Serum Bactericidal Test; Sputum; Tuberculosis | 2004 |
Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Therapy, Combination; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Sputum; Tuberculosis, Pulmonary | 2005 |
[Cervical spondylodiscitis: one pathogen may hide another].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Cervical Vertebrae; Cholecystitis; Discitis; Disease Progression; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Ethambutol; Fluoroquinolones; France; Humans; Immobilization; Isoniazid; Male; Middle Aged; Morocco; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Radiography; Rifampin; Tuberculosis, Spinal | 2006 |
Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Tuberculosis, Pulmonary | 2006 |
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Tuberculosis, Pulmonary | 2006 |
Moxifloxacin-induced arthropathy.
Topics: Aged, 80 and over; Antitubercular Agents; Arthritis; Aza Compounds; Drug Therapy, Combination; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Tuberculosis, Pulmonary | 2007 |
Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Synergism; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Time Factors | 2006 |
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Secondary Prevention; Time Factors; Tuberculosis | 2007 |
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Recurrence; Rifampin; Time Factors; Treatment Outcome; Tuberculosis | 2008 |
Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Cells, Cultured; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin | 2009 |
Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug?
Topics: Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2009 |
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
Topics: Antitubercular Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambutol; Fluoroquinolones; Humans; In Vitro Techniques; Isoniazid; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2010 |
Simultaneous scrofuloderma and intracranial tuberculomas: a rare presentation of systemic tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; Brain; Diagnosis, Differential; Drug Therapy, Combination; Fluoroquinolones; Humans; Isoniazid; Lichenoid Eruptions; Male; Middle Aged; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Treatment Outcome; Tuberculoma, Intracranial; Tuberculosis, Cutaneous | 2010 |
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Isoniazid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Streptomycin; Thienamycins | 2010 |
Torticollis in mice intravenously infected with Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Autopsy; Aza Compounds; Disease Models, Animal; Drug Therapy, Combination; Ear, Middle; Female; Fluoroquinolones; Injections, Intravenous; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Otitis Media; Pyrazinamide; Quinolines; Rifampin; Torticollis; Tuberculosis | 2011 |
Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication.
Topics: Antitubercular Agents; Aza Compounds; Biopsy; Brain; Cerebrospinal Fluid; Drug Resistance, Bacterial; Ethambutol; Female; Fluoroquinolones; Histocytochemistry; Humans; Isoniazid; Magnetic Resonance Imaging; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tomography, X-Ray Computed; Treatment Outcome; Tuberculoma, Intracranial; Tuberculosis, Multidrug-Resistant; Young Adult | 2011 |
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Spain; Tuberculosis | 2011 |
Pyrazinamide-induced sideroblastic anemia.
Topics: 5-Aminolevulinate Synthetase; alpha-Thalassemia; Anemia, Sideroblastic; Antitubercular Agents; Aza Compounds; Bone Marrow; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Hemolysis; Humans; Isoniazid; Middle Aged; Moxifloxacin; Peritonitis, Tuberculous; Pyrazinamide; Pyridoxine; Quinolines; Rifampin | 2012 |
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
Topics: Animals; Antitubercular Agents; Aza Compounds; Biological Availability; Disease Models, Animal; Drug Administration Schedule; Female; Fluoroquinolones; Granuloma; Humans; Isoniazid; Lung; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rabbits; Rifampin; Tissue Extracts; Tuberculosis, Pulmonary | 2012 |
Application of a microcalorimetric method for determining drug susceptibility in mycobacterium species.
Topics: Antitubercular Agents; Aza Compounds; Calorimetry; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium; Mycobacterium smegmatis; Mycobacterium tuberculosis; Quinolines | 2012 |
Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Markov Chains; Mice; Models, Theoretical; Moxifloxacin; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Quinolines; Rifampin; Tuberculosis, Multidrug-Resistant | 2012 |
Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB.
Topics: Amikacin; Antitubercular Agents; Aza Compounds; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Quinolines; Rifampin; Statistics, Nonparametric; Tuberculosis, Multidrug-Resistant | 2012 |
In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.
Topics: Animals; Antitubercular Agents; Aza Compounds; Chronic Disease; Clofazimine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Isoniazid; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Time Factors; Tuberculosis, Pulmonary | 2012 |
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins | 2012 |
Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin.
Topics: Adult; Area Under Curve; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rifampin; Tuberculosis | 2012 |
Salvage therapy for multidrug-resistant tuberculosis.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Capreomycin; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Male; Moxifloxacin; Mycobacterium tuberculosis; Retrospective Studies; Rifampin; Salvage Therapy; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2014 |
Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs.
Topics: Antitubercular Agents; Ethambutol; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Rifampin | 2014 |
Multidrug-resistant tuberculosis in Western Australia, 1998-2012.
Topics: Adolescent; Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Child; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Hospitalization; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Retrospective Studies; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Western Australia; Young Adult | 2014 |
Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.
Topics: Antitubercular Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Epithelial Cells; Fibroblasts; Fluoroquinolones; Humans; Isoenzymes; Isoniazid; Lung; Matrix Metalloproteinases; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Primary Cell Culture; Rifampin; Stromal Cells; Tuberculosis, Pulmonary | 2014 |
Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs.
Topics: Antitubercular Agents; Base Sequence; Colorimetry; Drug Resistance, Bacterial; Ethionamide; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Open Reading Frames; Rifabutin; Rifampin; Sequence Analysis, DNA; Tuberculosis | 2014 |
False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene.
Topics: Aged; Amikacin; Amino Acid Sequence; Antibiotics, Antitubercular; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Fluoroquinolones; Genotype; Humans; Isoniazid; Male; Molecular Sequence Data; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Phenotype; Pyrazinamide; Rifampin; Sensitivity and Specificity; Sputum; Tuberculosis, Pulmonary | 2014 |
Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis.
Topics: Adult; Antitubercular Agents; Dasatinib; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Moxifloxacin; Peritonitis, Tuberculous; Protein Kinase Inhibitors; Pyrazinamide; Pyrimidines; Thiazoles | 2015 |
Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study.
Topics: Adult; Aged; Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Greece; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Outpatients; Rifampin; Tuberculosis, Pulmonary | 2015 |
Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2016 |
Development and Optimization of Dual Drugs (Isoniazid and Moxiflox-acin) Loaded Functional PLGA Nanoparticles for the Synergistic Treatment of Tuberculosis.
Topics: Anti-Bacterial Agents; Drug Carriers; Drug Liberation; Drug Resistance, Bacterial; Drug Resistance, Multiple; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Lactic Acid; Magnetic Resonance Spectroscopy; Microscopy, Electron, Scanning; Moxifloxacin; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spectroscopy, Fourier Transform Infrared; Tuberculosis | 2016 |
[Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB].
Topics: Aminosalicylic Acids; Antibiotics, Antitubercular; Drug Synergism; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Retreatment; Rifabutin; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Donor-derived tuberculosis (TB): isoniazid-resistant TB transmitted from a lung transplant donor with inadequately treated latent infection.
Topics: Adult; Allografts; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antitubercular Agents; Bacteremia; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cystic Fibrosis; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Immunosuppression Therapy; Isoniazid; Latent Tuberculosis; Lung Transplantation; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pseudomonas aeruginosa; Rifampin; Tissue Donors; Tuberculosis, Pulmonary | 2016 |
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Clofazimine; Depression; Drug Costs; Emigrants and Immigrants; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Health Care Costs; Humans; India; Isoniazid; Linezolid; Male; Mediastinum; Microbial Sensitivity Tests; Moxifloxacin; New Zealand; Pyrazinamide; Radiography, Thoracic; Rifampin; Schizophrenia, Paranoid; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pleural; Tuberculosis, Pulmonary | 2016 |
Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; World Health Organization | 2017 |
Thiazomycin, nocathiacin and analogs show strong activity against clinical strains of drug-resistant Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Intercellular Signaling Peptides and Proteins; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Peptides; Peptides, Cyclic; Rifampin; Solubility; Thiazoles | 2017 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Mycobacterium tuberculosis Proteome Response to Antituberculosis Compounds Reveals Metabolic "Escape" Pathways That Prolong Bacterial Survival.
Topics: Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Isoniazid; Mefloquine; Moxifloxacin; Mycobacterium tuberculosis; Proteome; Proteomics; Rifampin | 2017 |
Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data.
Topics: Antitubercular Agents; Ciprofloxacin; Ethambutol; Humans; Isoniazid; Machine Learning; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Rifampin; Sequence Analysis, DNA; Streptomycin; Tuberculosis, Multidrug-Resistant | 2018 |
Antituberculosis Treatment in a Patient with Celiac Disease.
Topics: Aged; Antitubercular Agents; Celiac Disease; Diarrhea; Diet, Gluten-Free; Drug Compounding; Drug Substitution; Drug Therapy, Combination; Ethambutol; Glutens; Hemoptysis; Humans; Isoniazid; Male; Metronidazole; Moxifloxacin; Pyrazinamide; Rifampin; Smoking; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2018 |
[Optochiasmatic tuberculomas as a paradoxical reaction to treatment for meningeal tuberculosis].
Topics: Adult; Antitubercular Agents; Brain Infarction; Diagnostic Errors; Disease Progression; Drug Resistance, Microbial; Drug Substitution; Ethambutol; Female; Host-Pathogen Interactions; Humans; Isoniazid; Magnetic Resonance Imaging; Meningitis, Viral; Moxifloxacin; Mycobacterium tuberculosis; Neuroimaging; Optic Chiasm; Paresis; Prednisone; Pyrazinamide; Rifampin; Thalamus; Tuberculoma; Tuberculosis, Meningeal; Vision Disorders | 2018 |
Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Tuberculosis, Pulmonary | 2018 |
Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Topics: Adult; Antitubercular Agents; Clinical Protocols; Ethambutol; Female; HIV Seropositivity; Humans; Incidence; Isoniazid; Male; Moxifloxacin; Treatment Outcome; Tuberculosis, Pulmonary | 2018 |
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Host-Pathogen Interactions; Humans; Immunity, Innate; Isoniazid; Kanamycin; Macrophages; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prothionamide; Pyrazinamide; Time Factors; Tuberculosis, Multidrug-Resistant | 2018 |
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Ethambutol; Humans; Isoniazid; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Sputum; Tuberculosis | 2018 |
Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria.
Topics: Adenosine Triphosphate; Anti-Bacterial Agents; Antitubercular Agents; Bacterial Proteins; Drug Design; Electron Transport Chain Complex Proteins; Energy Metabolism; Isoniazid; Moxifloxacin; Mycobacterium; Oxidative Phosphorylation; Proton-Translocating ATPases | 2019 |
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Drug Tolerance; Ethambutol; Genome, Bacterial; Hydroxyl Radical; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Oxidation-Reduction; Oxidative Stress | 2020 |
Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients.
Topics: Ethambutol; Humans; Isoniazid; Lung; Lung Transplantation; Moxifloxacin; Pyrazinamide; Rifamycins; Transplant Recipients; Treatment Outcome; Tuberculosis | 2021 |
Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.
Topics: Adult; Amikacin; Antitubercular Agents; Clofazimine; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female; Humans; Isoniazid; Lost to Follow-Up; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pakistan; Pyrazinamide; Retrospective Studies; Survival Analysis; Treatment Failure; Tuberculosis, Multidrug-Resistant | 2021 |
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis, Pulmonary; United States | 2022 |
Use of Whole-Genome Sequencing to Predict
Topics: Amikacin; Aminosalicylic Acid; Antitubercular Agents; China; Cycloserine; Drug Resistance; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Rifampin; Streptomycin; Tuberculosis, Multidrug-Resistant | 2022 |
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifabutin; Tuberculosis | 2022 |
Prediction of Mycobacterium tuberculosis drug resistance by nucleotide MALDI-TOF-MS.
Topics: Amikacin; Antitubercular Agents; China; Drug Resistance; Ethambutol; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nucleotides; Ofloxacin; Rifampin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Streptomycin; Tuberculosis, Lymph Node | 2022 |
Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pregnanes; Pyrazinamide; Rifampin; South Africa; Tuberculosis | 2022 |
RNase HI Depletion Strongly Potentiates Cell Killing by Rifampicin in Mycobacteria.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Cell Death; Humans; Isoniazid; Moxifloxacin; Mycobacterium Infections; Mycobacterium tuberculosis; Rifampin; RNA; Streptomycin; Tuberculosis, Multidrug-Resistant | 2022 |
In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Genotype; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization | 2022 |
A case of ascetic fluid Mycobacterium aubagnense infection in a patient with severe peritoneal effusion.
Topics: Ascites; Ascitic Fluid; Diuretics; Ethambutol; Humans; Isoniazid; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria | 2023 |
The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability.
Topics: Animals; Antitubercular Agents; Biological Availability; Dysbiosis; Humans; Isoniazid; Mice; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis | 2023 |
Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
Topics: Antitubercular Agents; beta-Lactamase Inhibitors; Humans; Isoniazid; Linezolid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Multidrug-Resistant | 2023 |
Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Latvia; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing | 2023 |
Protein binding investigation of first-line and second-line antituberculosis drugs.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein Binding; Pyrazinamide; Rifampin; Tuberculosis | 2023 |
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.
Topics: Amikacin; Antitubercular Agents; Humans; Isoniazid; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; Verapamil | 2023 |